NTRA
Natera, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Strong buy
+60/100
Last price
405.00
▼ 20.64 (4.85%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
427.00
Prev close
425.64
Day high
437.41
Day low
394.77
Volume
2.50M
Market cap
$57.75B
P/E (TTM)
—
52W range
167.99 – 437.41
Day trading desk
Gap from prior close
+0.32%
Prior close 425.64
VWAP
402.53
+0.61% from price
Relative volume
3.40×
Unusually busy
Session range
13.58%
394.01 – 447.53
Position in range
21%
Near session low
ATR (14D)
17.23
4.26% of price
Prior day high
427.18
PDH
Prior day low
405.24
PDL
Bid / ask spread
—
Quote not published
Session volume
4.76M
Avg 1.40M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.35%
-5.3%
1M
+22.08%
+20.9%
3M
+46.01%
+41.5%
6M
+91.45%
+73.3%
YTD
+74.89%
+60.6%
1Y
+139.41%
+123.0%
3Y
+805.42%
+723.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on NTRA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-475.12K
Net selling
Buy transactions
21
107.40K shares
Sell transactions
55
582.53K shares
Net transactions
+76
Buys less sells
Sell : buy shares
5.4 : 1
Heavily one-sided
Insider-held shares
3.95M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 15, 26 | RABINOWITZ MATTHEW Officer and Director |
SELL | 102.00K | $34.80M | |
| Sep 11, 26 | RABINOWITZ MATTHEW Officer and Director |
SELL | 50.00K | $16.40M | Direct |
| Sep 2, 26 | MOSHKEVICH SOLOMON Officer |
SELL | 18.16K | $5.92M | Direct |
| Sep 1, 26 | CHAPMAN STEVEN LEONARD Chief Executive Officer |
SELL | 1.70K | $545.04K | Direct |
| Aug 10, 26 | SHEENA JONATHAN Director |
SELL | 6.00K | $1.95M | Direct |
| Aug 10, 26 | FESKO JOHN President |
SELL | 6.52K | $2.10M | Direct |
| Aug 7, 26 | SHEENA JONATHAN Director |
SELL | 9.15K | $2.89M | Direct |
| Aug 7, 26 | RABINOWITZ MATTHEW Officer and Director |
SELL | 2.00K | $641.80K | Indirect |
| Aug 6, 26 | FESKO JOHN President |
STOCK | 20.00K | $0 | Direct |
| Aug 4, 26 | BROPHY MICHAEL BURKES Chief Financial Officer |
SELL | 795 | $216.03K | Direct |
| Aug 3, 26 | SHEENA JONATHAN Director |
SELL | 109 | $29.21K | Direct |
| Aug 3, 26 | RABINOWITZ MATTHEW Officer and Director |
SELL | 731 | $195.90K | Direct |
| Aug 3, 26 | FESKO JOHN President |
SELL | 295 | $79.06K | Direct |
| Aug 3, 26 | MOSHKEVICH SOLOMON Officer |
SELL | 3.41K | $905.63K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAYNES ROY D |
Director | 20.16K | Stock Award(Grant) |
BOTHA ROELOF FREDERICK |
Director | 1.08M | Stock Award(Grant) |
BROPHY MICHAEL BURKES |
Chief Financial Officer | 51.64K | Sale |
CHAPMAN STEVEN LEONARD |
Chief Executive Officer | 98.20K | Sale |
FESKO JOHN |
President | 197.26K | Sale |
HEALY JAMES I |
Director | 1.60M | Stock Award(Grant) |
MOSHKEVICH SOLOMON |
Officer | 110.86K | Sale |
RABINOWITZ DANIEL A |
Officer | 170.07K | Sale |
RABINOWITZ MATTHEW |
Officer and Director | — | Sale |
SHEENA JONATHAN |
Director | 266.53K | Sale |
Fundamentals
Market cap$57.75B
Enterprise value$56.90B
Revenue (TTM)$2.71B
Gross profit$1.77B
EBITDA$-224.42M
Net income$-192.35M
EPS (TTM)$-1.35
Free cash flow$104.03M
Total cash$1.09B
Total debt$238.49M
Book value / share$12.68
Shares outstanding144.14M
Float140.12M
Short % of float3.43%
Dividend yield0.00%
Beta (5Y)1.50
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2,356.35
PEG ratio—
Price / sales—
Price / book31.59
EV / revenue21.02
EV / EBITDA-253.53
Gross margin65.23%
Operating margin-10.29%
Profit margin-7.11%
Return on equity-12.54%
Return on assets-8.08%
Debt / equity13.09
Current ratio3.00
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.31B | $1.70B | $1.08B | $820.22M | +35.9% |
| Operating revenue | $2.31B | $1.70B | $1.08B | $820.22M | +35.9% |
| Cost of revenue | $812.93M | $673.75M | $589.83M | $456.26M | +20.7% |
| Gross profit | $1.49B | $1.02B | $492.74M | $363.97M | +45.9% |
| Research & development | $624.11M | $404.14M | $320.68M | $316.42M | +54.4% |
| Selling, general & admin | $1.18B | $841.31M | $618.31M | $588.59M | +39.9% |
| Total operating expense | $1.80B | $1.25B | $938.99M | $905.01M | +44.8% |
| Operating income | -$309.91M | -$222.29M | -$446.25M | -$541.04M | -39.4% |
| Net interest income | $41.82M | $32.56M | $11.71M | -$5.78M | +28.4% |
| Pre-tax income | -$268.09M | -$189.73M | -$434.53M | -$546.82M | -41.3% |
| Tax provision | -$59.93M | $695.00K | $271.00K | $978.00K | -8,722.9% |
| Net income | -$208.16M | -$190.43M | -$434.80M | -$547.80M | -9.3% |
| Net income to common | -$208.16M | -$190.43M | -$434.80M | -$547.80M | -9.3% |
| Basic EPS | -1.52 | -1.53 | -3.78 | -5.57 | +0.7% |
| Diluted EPS | -1.52 | -1.53 | -3.78 | -5.57 | +0.7% |
| EBIT | -$264.02M | -$179.05M | -$421.89M | -$537.50M | -47.5% |
| EBITDA | -$220.54M | -$148.08M | -$397.80M | -$520.80M | -48.9% |
| Basic shares | 136.72M | 124.72M | 115.00M | 98.41M | +9.6% |
| Diluted shares | 136.72M | 124.72M | 115.00M | 98.41M | +9.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.08B | $945.59M | $642.10M | $466.09M | — | +13.8% |
| Cash & short-term investments | $1.08B | $968.28M | $878.98M | $898.39M | — | +11.1% |
| Accounts receivable | $296.53M | $314.17M | $278.29M | $244.38M | — | -5.6% |
| Inventory | $68.44M | $44.74M | $40.76M | $35.41M | — | +53.0% |
| Total current assets | $1.50B | $1.38B | $1.26B | $1.21B | — | +8.8% |
| Property, plant & equipment | $349.73M | $248.19M | $167.75M | $164.33M | — | +40.9% |
| Goodwill & intangibles | $514.78M | $10.93M | — | — | — | +4,608.5% |
| Total assets | $2.40B | $1.66B | $1.44B | $1.39B | — | +44.4% |
| Total current liabilities | $441.23M | $344.05M | $307.27M | $310.50M | — | +28.2% |
| Current debt | $80.32M | $80.36M | $80.40M | $80.35M | — | -0.0% |
| Long-term debt | — | — | $282.94M | $281.65M | $280.39M | — |
| Total debt | $214.38M | $187.12M | $441.99M | $446.22M | — | +14.6% |
| Total liabilities | $685.93M | $465.31M | $676.37M | $688.73M | — | +47.4% |
| Retained earnings | -$2.78B | -$2.57B | -$2.38B | -$1.94B | — | -8.1% |
| Shareholder equity | $1.71B | $1.20B | $765.33M | $705.74M | — | +43.2% |
| Working capital | $1.06B | $1.03B | $951.27M | $901.32M | — | +2.3% |
| Net tangible assets | $1.20B | $1.18B | $765.33M | $705.74M | — | +1.1% |
| Shares issued | 139.69M | 132.65M | 119.58M | 111.25M | — | +5.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$208.16M | -$190.43M | -$434.80M | -$547.80M | -9.3% |
| Depreciation & amortisation | $43.48M | $30.97M | $24.10M | $16.70M | +40.4% |
| Stock-based compensation | $354.40M | $274.43M | $191.81M | $152.38M | +29.1% |
| Change in working capital | $10.04M | $2.14M | -$47.95M | -$83.15M | +369.2% |
| Operating cash flow | $215.30M | $135.66M | -$246.96M | -$431.50M | +58.7% |
| Capital expenditure | -$139.19M | -$76.92M | -$39.20M | -$47.70M | -81.0% |
| Investing cash flow | -$132.21M | $137.62M | $168.50M | $330.34M | -196.1% |
| Financing cash flow | $47.46M | $30.20M | $254.46M | $482.64M | +57.1% |
| Free cash flow | $76.11M | $58.75M | -$286.15M | -$479.20M | +29.6% |
| End cash position | $1.08B | $945.59M | $642.10M | $466.09M | +13.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $752.75M | $696.64M | $665.50M | $592.18M | $546.60M | — | +8.1% |
| Operating revenue | $752.75M | $696.64M | $665.50M | $592.18M | $546.60M | — | +8.1% |
| Cost of revenue | $267.56M | $245.81M | $220.07M | $207.80M | $200.00M | — | +8.8% |
| Gross profit | $485.19M | $450.83M | $445.43M | $384.38M | $346.60M | — | +7.6% |
| Research & development | $228.07M | $210.70M | $175.19M | $173.41M | $146.43M | — | +8.2% |
| Selling, general & admin | $327.20M | $327.94M | $291.30M | $308.55M | $310.55M | — | -0.2% |
| Total operating expense | $560.98M | $544.35M | $468.21M | $481.96M | $456.98M | — | +3.1% |
| Operating income | -$75.79M | -$93.52M | -$22.79M | -$97.58M | -$110.37M | — | +19.0% |
| Net interest income | $8.56M | $8.71M | $9.46M | $10.24M | $9.71M | — | -1.7% |
| Pre-tax income | -$67.23M | -$84.81M | -$13.33M | -$87.34M | -$100.66M | — | +20.7% |
| Tax provision | -$261.00K | $283.00K | -$60.58M | $207.00K | $275.00K | — | -192.2% |
| Net income | -$66.97M | -$85.09M | $47.26M | -$87.54M | -$100.94M | — | +21.3% |
| Net income to common | -$66.97M | -$85.09M | $47.26M | -$87.54M | -$100.94M | — | +21.3% |
| Basic EPS | -0.47 | -0.60 | — | -0.64 | -0.74 | -0.50 | +21.7% |
| Diluted EPS | -0.47 | -0.60 | — | -0.64 | -0.74 | -0.50 | +21.7% |
| EBIT | -$66.34M | -$83.92M | -$12.34M | -$86.29M | -$99.63M | — | +20.9% |
| EBITDA | -$45.15M | -$63.69M | $1.76M | -$76.00M | -$89.78M | — | +29.1% |
| Basic shares | 143.28M | 141.50M | — | 137.19M | 136.39M | 134.75M | +1.3% |
| Diluted shares | 143.28M | 141.50M | — | 137.19M | 136.39M | 134.75M | +1.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.09B | $1.09B | $1.08B | $1.04B | $1.00B | +0.3% |
| Cash & short-term investments | $1.09B | $1.09B | $1.08B | $1.04B | $1.02B | +0.3% |
| Accounts receivable | $421.97M | $417.60M | $296.53M | $286.38M | $309.22M | +1.0% |
| Inventory | $80.35M | $70.72M | $68.44M | $64.64M | $54.27M | +13.6% |
| Total current assets | $1.66B | $1.65B | $1.50B | $1.45B | $1.43B | +0.4% |
| Property, plant & equipment | $447.25M | $403.37M | $349.73M | $303.48M | $284.35M | +10.9% |
| Goodwill & intangibles | $501.30M | $508.22M | $514.78M | — | — | -1.4% |
| Total assets | $2.66B | $2.61B | $2.40B | $1.82B | $1.76B | +1.6% |
| Total current liabilities | $553.20M | $558.26M | $441.23M | $442.02M | $384.84M | -0.9% |
| Current debt | $80.29M | $80.31M | $80.32M | $80.34M | $80.34M | -0.0% |
| Total debt | $238.49M | $240.08M | $214.38M | $198.73M | $196.13M | -0.7% |
| Total liabilities | $836.00M | $840.38M | $685.93M | $569.29M | $510.88M | -0.5% |
| Retained earnings | -$2.93B | -$2.86B | -$2.78B | -$2.82B | -$2.74B | -2.3% |
| Shareholder equity | $1.82B | $1.77B | $1.71B | $1.25B | $1.25B | +2.7% |
| Working capital | $1.11B | $1.09B | $1.06B | $1.01B | $1.05B | +1.1% |
| Net tangible assets | $1.32B | $1.27B | $1.20B | $1.25B | $1.25B | +4.3% |
| Shares issued | 143.61M | 142.73M | 139.69M | 137.53M | 136.76M | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$66.97M | -$85.09M | $47.26M | -$87.54M | -$100.94M | +21.3% |
| Depreciation & amortisation | $21.19M | $20.23M | $14.10M | $10.29M | $9.86M | +4.8% |
| Stock-based compensation | $103.10M | $95.11M | $92.58M | $90.64M | $93.36M | +8.4% |
| Change in working capital | -$3.86M | -$2.83M | -$85.08M | $40.93M | $30.80M | -36.7% |
| Operating cash flow | $54.79M | $40.17M | $73.89M | $59.39M | $37.57M | +36.4% |
| Capital expenditure | -$63.43M | -$22.14M | -$56.57M | -$34.91M | -$25.90M | -186.5% |
| Investing cash flow | -$63.43M | -$32.14M | -$71.59M | -$19.91M | -$23.90M | -97.4% |
| Financing cash flow | $12.21M | $3.76M | $32.41M | $1.94M | $12.58M | +224.8% |
| Free cash flow | -$8.64M | $18.03M | $17.32M | $24.48M | $11.68M | -147.9% |
| End cash position | $1.09B | $1.09B | $1.08B | $1.04B | $1.00B | +0.3% |
Options analytics
Put / call volume
1.16
Put-heavy session
Put / call open interest
2.00
Positioning, not flow
Max pain
380.00
-5.2% from spot
ATM implied vol
51.7%
Nearest strike to spot
Skew (10% OTM)
+0.7%
Puts bid over calls
Call volume
667
Contracts, this expiry
Put volume
775
Contracts, this expiry
Heaviest call OI
380.00
546 contracts
Heaviest put OI
290.00
1.19K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.53 | -0.47 | +12.0% |
| Mar 2026 | -0.55 | -0.60 | -8.5% |
| Dec 2025 | -0.53 | 0.36 | +167.5% |
| Sep 2025 | -0.35 | -0.64 | -80.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.27 | 15 | $707.78M | +19.5% |
| Next quarter | -0.10 | 14 | $749.28M | +12.6% |
| Current year | -1.44 | 16 | $2.91B | +26.2% |
| Next year | -0.17 | 16 | $3.51B | +20.6% |
Analyst targets & ownership
Mean target$377.43
High target$480.00
Low target$280.00
Implied upside-6.81%
Analyst count22
ConsensusSTRONG BUY
Strong buy / Buy5 / 16
Hold2
Sell / Strong sell0 / 0
Held by insiders2.74%
Held by institutions96.75%
Institutions holding1.20K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
409.69
-1.14% from price
SMA 20
380.87
+5.19% from price
SMA 50
337.20
+18.82% from price
SMA 100
288.24
+40.51% from price
SMA 200
250.92
+59.67% from price
EMA 12
400.12
+1.22% from price
EMA 26
376.19
+7.66% from price
EMA 50
345.80
+17.12% from price
RSI (14)
62.9
Neutral
MACD (12,26,9)
23.93
Hist 0.27
ATR (14)
17.23
4.30% of price
Realised vol 30D
39.0%
Annualised
Bollinger upper
446.51
20, 2σ
Bollinger lower
315.23
20, 2σ
50 / 200 cross
Golden
337.20 vs 250.92
Trend bias
Above 200
+59.67%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.22
More volatile than market
Correlation to SPY
0.33
Loosely linked
Realised vol 30D
39.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-28.2%
Peak to trough
Max drawdown 5Y
-76.4%
Peak to trough
ATR 14
17.23
4.30% of price
Beta (reported)
1.50
5Y monthly, from filing
Short interest
Shares short
4.80M
Prior 4.30M
Change vs prior
+11.7%
Shorts adding
% of float
3.43%
Normal
% of shares out
3.33%
Against total outstanding
Days to cover
4.1
Liquid
Float
140.12M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Oct 1, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Sep 25, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Sep 9, 26 | UBS | MAINTAINED | Buy | Buy |
| Sep 8, 26 | Rothschild & Co | INITIATED | — | Buy |
| Aug 13, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Aug 12, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 12, 26 | Stephens & Co. | MAINTAINED | Overweight | Overweight |
| Aug 12, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 7, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 7, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Aug 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-06
Corporate Changes & Voting Matters
8-K/A · 2026-06-16
Corporate Changes & Voting Matters
8-K · 2026-06-05
Periodic Financial Reports
10-Q · 2026-05-08
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-23
Headlines
1 Unpopular Stock That Deserves Some Love and 2 Facing Challenges
StockStory · 13h ago
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Business Wire · 15h ago
2 Growth Stocks to Stash and 1 That Underwhelm
StockStory · 1d ago
Natera Launches Phase III MRD-Guided Breast Cancer Trial Using Signatera
InvestorsHub · 2d ago
Natera, Alliance Foundation Trials Launch Phase 3 Trial for Breast Cancer Treatment Strategy
MT Newswires · 2d ago
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Business Wire · 2d ago
3 Great Healthcare Stocks To Own In October 2026
Simply Wall St. · 5d ago
1 Unprofitable Stock to Target This Week and 2 We Question
StockStory · 7d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.